References
- 1. Clitherow JW, Mitchard M, Harper NJ. The possible biological function of pseudo-cholinesterase. Nature 1963;199:1000-1. doi:10.1038/1991000a010.1038/1991000a0
- 2. Kutty KM. Biological function of cholinesterase. Clin Biochem 1980;13:239-43. doi: 10.1016/S0009-9120(80)80001-4701159210.1016/S0009-9120(80)80001-4
- 3. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50:433-50. doi: 10.1016/j.phrs.2003.11.0171530424010.1016/j.phrs.2003.11.017
- 4. Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJ, Heine RJ. Is pseudocholinesterase activity related to markers of triacalglycerol synthesis in type II diabetes mellitus? Clin Sci (Lond) 2001;101:29-35. doi: 10.1042/cs101002910.1042/cs1010029
- 5. Kálmán J, Juhász A, Rakonczay Z, Abrahám G, Zana M, Boda K, Farkas T, Penke B, Janka Z. Increased serum butyrylcholinesterase activity in type IIb hyperlipidaemic patients. Life Sci 2004;75:1195-204. doi: 10.1016/j.lfs.2004.02.01910.1016/j.lfs.2004.02.019
- 6. Cokuğraş AN. Butyrylcholinesterase: structure and physiological importance. Turk J Biochem 2003;28:54-61.
- 7. Chen VP, Gao Y, Geng L, Brimijoin S. Butyrylcholinesterase regulates central ghrelin signaling and has an impact on food intake and glucose homeostasis. Int J Obes (Lond) 2017;41:1413-9. doi: 10.1038/ijo.2017.12310.1038/ijo.2017.123
- 8. Milić M, Žunec S, Micek V, Kašuba V, Mikolić A, Lovaković BT, Semren TŽ, Pavičić I, Marjanović Čermak AM, Pizent A, Lucić Vrdoljak A, Valencia-Quintana R, Sánchez-Alarcón J, Želježić D. Oxidative stress, cholinesterase activity, and DNA damage in the liver, whole blood, and plasma of Wistar rats following a 28-day exposure to glyphosate. Arh Hig Rada Toksikol 2018;69:154-68. doi: 10.2478/aiht-2018-69-3114
- 9. Pohanka M. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. Int J Mol Sci 2014;15:9809-25. doi: 10.3390/ijms1506980910.3390/ijms15069809
- 10. Lucić Vrdoljak A, Bradamante V, Radić B, Peraica M, Fuchs R, Reiner Z. Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats. Acta Pharm 2005;55:177-85. PMID: 16179131
- 11. Bradamante V, Kunec-Vajić E, Lisić M, Dobrić I, Beus I. Plasma cholinesterase activity in patients during therapy with dexamethasone or prednisone. Eur J Clin Pharmacol 1989;36:253-7. doi: 10.1007/BF0055815610.1007/BF00558156
- 12. Barabas E, Zsigmond EK, Kirkpatrick AF. The inhibitory effect of esmolol on human plasmacholinesterase. Can Anaesth Soc J 1986;33:332-5. doi: 10.1007/BF0301074610.1007/BF03010746
- 13. Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf 1996;15:261-73. doi: 10.2165/00002018-199615040-0000410.2165/00002018-199615040-00004
- 14. Geula C, Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer’s disease. Drugs Today (Barc) 2004;40:711-21. doi: 10.1358/dot.2004.40.8.85047310.1358/dot.2004.40.8.850473
- 15. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009;1:7. doi: 10.1186/alzrt710.1186/alzrt7
- 16. Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem 2004;37:42-9. doi: 10.1016/j.clinbiochem.2003.09.00410.1016/j.clinbiochem.2003.09.004
- 17. Cibicková L, Palicka V, Cibicek N, Cermáková E, Micuda S, Bartosová L, Jun D. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol Res 2007;56:765-70. PMID: 17087598
- 18. Macan M, Vukšić A, Žunec S, Konjevoda P, Lovrić J, Kelava M, Štambuk N, Vrkić N, Bradamante V. Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats. Pharmacol Rep 2015;67:907-13. doi: 10.1016/j.pharep.2015.02.00510.1016/j.pharep.2015.02.005
- 19. Kunec-Vajić E, Bernat N, Muacević-Katanec D. Effect of hypolipidemic drugs on cholinesterase activity in the rat. Gen Pharmacol 1992;23:217-9. doi: 10.1016/0306-3623(92)90013-A10.1016/0306-3623(92)90013-
- 20. Bradamante V, Vrkić N, Lucić A, Radić B, Macan M. Interrelated effects of high sucrose diet and gemfibrozil on butyrylcholinesterase activity and plasma lipids in rats. Period Biol 2005;107:189-93.
- 21. Muačević-Katanec D, Bradamante V, Reiner Ž, Sučić M, Poljičanin T, Bušljeta I, Metelko Ž. Clinical study on the effect of simvastatin on butyrylcholinesterase activity. Arzneimittel-Forschung 2005;55:271-5. doi: 10.1055/s-0031-129685610.1055/s-0031-1296856
- 22. Guillen J. FELASA guidelines and recommendations. J Am Assoc Lab Anim Sci 2012;51:311-21. PMCID: PMC3358979
- 23. Deckardt K, Weber I, Kaspers U, Hellwig J, Tennekes H, van Ravenzwaay B. The effects of inhalation anaesthetics on common clinical pathology parameters in laboratory rats. Food Chem Toxicol 2007;45:1709-18. doi: 10.1016/j.fct.2007.03.00510.1016/j.fct.2007.03.005
- 24. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new rapid colorimetric determination of acetycholinesterase activity. Biochem Pharmacol 1961;7:88-95. doi: 10.1016/0006-2952(61)90145-910.1016/0006-2952(61)90145-9
- 25. Rowe P. Essential Statistics for the Pharmaceutical Sciences. 2nd ed. Chichester: Wiley-Blackwell; 2007.
- 26. Cibicková L, Hyspler R, Micuda S, Cibicek N, Zivna H, Jun D, Ticha A, Brcakova E, Palicka V. The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. Steroids 2009;74:13-9. doi: 10.1016/j.steroids.2008.08.00710.1016/j.steroids.2008.08.007
- 27. Dalla Y, Singh N, Jaggi AS, Singh D. Memory restorative role of statins in experimental dementia: an evidence of their cholesterol dependent and independent actions. Pharmacol Rep 2010;62:784-96. doi: 10.1016/S1734-1140(10)70339-X10.1016/S1734-1140(10)70339-X
- 28. Butler EG, England PJ, Williams GM. Effect of peroxisome proliferating hypolipidemic agents on serum activity levels of arylesterase and cholinesterase in rats and mice. Res Commun Chem Pathol Pharmacol 1988;60:125-8. PMID: 3381006
- 29. Hashimoto F, Ishikawa T, Hamada S, Hayashi H. Effect of gemfibrozil on lipid biosynthesis from acetyl-CoA derived from peroxisomal beta-oxidation. Biochem Pharmacol 1995;49:1213-21. doi: 10.1016/0006-2952(95)00041-W10.1016/0006-2952(95)00041-
- 30. Sisková K, Bilka F, Adameová A, Balazová A, Mydla M, Pauliková I. Influence of lipid imbalance on butyrylcholinesterase activity and biotransformation efficiency. Pharmazie 2012;67:345-50. doi: 10.1691/ph.2012.165310.1691/ph.2012.1653
- 31. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statininduced inhibition of the Rho-signaling pathway activates PPAR alpha and induces HDL apoA-I. J Clin Invest 2001;107:1423-32. doi: 10.1172/JCI1085210.1172/JCI10852
- 32. Seo M, Inoue I, Ikeda M, Nakano T, Takahashi S, Katayama S, Komoda T. Statins activate human PPAR alpha promoter and increase PPAR alpha mRNA expression and activation in HepG2 cells. PPAR Res 2008;2008:316306. doi: 10.1155/2008/31630610.1155/2008/316306
- 33. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007;561:194-201. doi: 10.1016/j.ejphar.2006.12.02610.1016/j.ejphar.2006.12.026
- 34. Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, Díaz C, Hernández G, Laguna JC, Sánchez RM. Atorvastatin treatment induced peroxisome proliferatoractivated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002;302:232-9. doi: 10.1124/jpet.302.1.23210.1124/jpet.302.1.232
- 35. Grabacka M, Pierzchalska M, Dean M, Reiss K. Regulation of ketone body metabolism and the role of PPARα. Int J Mol Sci 2016;17:2093. doi: 10.3390/ijms1712209310.3390/ijms17122093
- 36. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutr J 2014;13:17. doi: 10.1186/1475-2891-13-1710.1186/1475-2891-13-17
- 37. Ferreira AV, Menezes-Garcia Z, Mario EG, Delpuerto HL, Martins AS, Botion LM. Increased expression of oxidative enzymes in adipose tissue following PPARα-activation. Metabolism 2014;63:456-60. doi: 10.1016/j.metabol.2013.12.00910.1016/j.metabol.2013.12.009
- 38. Kallai-Sanfacon MA, Cayen MN, Dubuc J, Greselin E, Dvornik D. Effect of AY-25,712 and other lipid-lowering agents on liver catalase and liver carnitine acetyltransferase in rats. Proc Soc Exp Biol Med 1983;173:367-71. doi: 10.3181/00379727-173-4165810.3181/00379727-173-41658
- 39. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 2006;26:613-20. doi: 10.1111/j.1478-3231.2006.01265.x10.1111/j.1478-3231.2006.01265.x
- 40. Roy A, Pahan K. PPARα signaling in the hippocampus: crosstalk between fat and memory. J Neuroimmune Pharmacol 2015;10:30-4. doi: 10.1007/s11481-014-9582-910.1007/s11481-014-9582-9
- 41. Lizard G, Rouaud O, Demarquoy J, Cherkaoui-Malki M, Iuliano L. Potential roles of peroxisomes in Alzheimer’s disease and in dementia of the Alzheimer’s type. J Alzheimers Dis 2012;29:241-54. doi: 10.3233/JAD-2011-11116310.3233/JAD-2011-11116322433776
- 42. Berger J, Dorninger F, Forss-Petter S, Kunze M. Peroxisomes in brain development and function. Biochim Biophys Acta 2016;1863:934-55. doi: 10.1016/j.bbamcr.2015.12.00510.1016/j.bbamcr.2015.12.005
- 43. Pytel E, Bukowska B, Koter-Michalak M, Olszewska-Banaszczyk M, Gorzelak-Pabiś P, Broncel M. Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease. Pharmacol Rep 2017;69:150-5. doi: 10.1016/j.pharep.2016.09.01610.1016/j.pharep.2016.09.016